Journal article

Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer

Edmond M Kwan, Arun A Azad

Current Opinion in Urology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020


Funding Acknowledgements

E.M.K. is supported by a National Health and Medical Research Council (NHMRC) Postgraduate Scholarship; A.A.A. is supported by aNHMRC project grant, Victorian Cancer Agency Clinical Research Fellowship and Astellas Investigator-initiated grant.